Journals / Osteoporoz Dünyasından / 2003 / Cilt: 9 - Sayı: 1

The effect of Alendronate and intranasal calcitonin treatments on bone mineral density in men with idiopathic osteoporosis

İdiopatik osteoporozu olan erkek hastalarda Alendronat ve kalsitonin tedavilerinin kemik mineral yoğunluğu üzerine etkilerinin karşılaştırılması

Pages
23–28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, alendronate seemed to be more effective than calcitonin, increasing both spinal and femoral BMD, for the treatment of idiopathic male osteoporosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to compare the effect of alend-ronate and calcitonin treatments on bone mineral density (BMD) in men with idiopathic osteoporosis.
📊
Key Findings & Data:After performing a detailed clinical and laboratory assessment in order to eliminate secondary factors that can lead to osteoporosis, fifty-two men with idiopathic osteoporosis were randomly assigned to two groups: 28 patients in the first group received intranasal salmon calcitonin at a dosage of 200 IU/ day and they also received daily doses of 1000 mg calcium supplements.
💡
Conclusion & Impact:In conclusion, alendronate seemed to be more effective than calcitonin, increasing both spinal and femoral BMD, for the treatment of idiopathic male osteoporosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Alendronat · Kemik yoğunluğu · Osteoporoz

Abstract

The aim of this study was to compare the effect of alend-ronate and calcitonin treatments on bone mineral density (BMD) in men with idiopathic osteoporosis. After performing a detailed clinical and laboratory assessment in order to eliminate secondary factors that can lead to osteoporosis, fifty-two men with idiopathic osteoporosis were randomly assigned to two groups: 28 patients in the first group received intranasal salmon calcitonin at a dosage of 200 IU/ day and they also received daily doses of 1000 mg calcium supplements. Twenty-four patients in the second group used 10 mg alendronate/day and 1000 mg calcium/day. DXA was used for the measurement of BMD of the lumbar spine and proximal femur before and after the study period. At the end of the treatment, alendronate produced significant increases in BMD at the lumbar spine (p< 0.001), femur neck (p<0.05), trochanteric region (p<0.05) and at the Ward triangle (p<0.05). In contrast, only a significant increase in BMD of the lumbar spine was observed with calcitonin treatment (p< 0.001) and intranasal calcitonin treatment failed to increase BMD in the femur neck, trochanteric region and Ward triangle (p>0.05). When the groups were compared with each other, a significant increase in lumbar BMD was obtained in favor of alendronate treatment (p<0.05). In conclusion, alendronate seemed to be more effective than calcitonin, increasing both spinal and femoral BMD, for the treatment of idiopathic male osteoporosis.

Özet

Bu çalışmanın amacı idiopatik osteoporozu olan erkek hastalarda alendronat ve kalsitonin tedavilerinin kemik mineral yoğunluğu (KMY) üzerindeki etkilerini araştırmaktı. Sekonder osteoporoza yol açabilecek nedenleri ekarte etmek amacıyla ayrıntılı bir klinik ve laboratuar değerlendirme yapıldıktan sonra, 52 hasta randomize olarak iki gruba ayrıldı. Yirmi sekiz hastadan oluşan 1. gruba 12 ay süreyle 200 IU/gün dozda intranazal salmon kalsitonini ve 1000 mg/gün dozda kalsiyum uygulandı. Yirmi dört hastadan oluşan 2. gruba ise yine 12 ay süreyle 10 mg/gün dozda alendronat ve 1000 mg/gün kalsiyum verildi. Çalışmanın başlangıcında ve sonunda DXA yöntemi ile hastaların lomber bölge, femur boynu, trokanterik bölge ve Ward üçgeni KMY ölçümleri gerçekleştirildi. Tedavi sonrasında, alendronat kullanan hastaların lomber bölge, femur boynu, trokanterik bölge ve Ward üçgeninde önemli KMY artışları oldu (sırasıyla p<0.001, p<0.05, p<0.05, p<0.05). Kalsitonin uygulanan hastaların ise sadece lomber bölge KMY' da artış görüldü (p<0.001), buna karşın femur boynu, trokanterik bölge ve Ward üçgeni KMY' da ise istatistiksel anlamı olan bir değişiklik gözlenmedi. Gruplar birbiri ile karşılaştırıldığında alendronat kullanan grubun lehine olmak üzere lomber bölge KMY' unda anlamlı bir artış olduğu görüldü (p<0.05). Elde ettiğimiz bu sonuçlar KMY' unu arttırmak açısından alendronat tedavisinin idiopatik erkek osteoporozunda daha etkili olduğunu düşündürdü.

🔖

Cite This Article

TAŞÇIOĞLU, F., AYDEMİR, A., ÖNER, C. (2003). The effect of Alendronate and intranasal calcitonin treatments on bone mineral density in men with idiopathic osteoporosis. Osteoporoz Dünyasından, Cilt: 9 - Sayı: 1, 23–28. https://ajindex.com/articles/286821

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Pietschmann P, Kudlacek J, Grisar J, et al. Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 2001; 31: 444-451
  2. Niewoehner C. Osteoporosis in men: is it more common than we think? Postgrad Med 1993; 93: 59-68
  3. Seeman E. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. Am J Med 1993; 95: 22-8
  4. Copper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285-289
  5. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16: 87-116
  6. Myers AH, Robinson EG, Van Natta ML, et al. Hip fractures among the elderly: Factors associated with in-hospital mortality. Am J Epidemiol 1991; 134: 1128-1137
  7. Poor G, Atkinson FJ, O’Fallon WM, Melton LJ. Determinants of reduced survival following hip fractures in men. Clin Orthop Rel Res 1995; 319: 260-265
  8. Melton LJ, Amadio PC, Crowson CS, O’Fallon WM. Long-term trends in the incidence of distal forearm fractures. Osteoporos Int 1998; 8: 341-348
  9. Trovas GP, Lyritis GP. Aetiology in male osteoporosis. J Bone Miner Res 1997; 12: 370
  10. Peris P, Guanabens N, Monegal A, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol 1995; 34: 936-941
  11. Allain T, Pitt P, Moniz C. Osteoporosis in men. Br Med J 1992; 305: 955-956
  12. Seeman E, Melton LJ, O’Fallon M, Riggs BL. Risk factors for osteoporosis in men. Am J Med 1983; 75: 977-83
  13. Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Inter Med 1995; 123: 452-460
  14. Murphy S, Khaw K, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Mineral 1993; 20: 133-40
  15. Gillberg P, Johansson AG, Ljunghall S. Decreased estradiol levels and free androgen index and elevated sex hormone-binding globulin levels in male idiopathic osteoporosis. Calcif Tissue Int 1999; 64: 209-213
  16. Braidman IP, Baris C, Selby PL, et al. Preliminary report of impaired oestrogen receptor-a expression, but no involvement of androgen receptor, in mail idiopathic osteoporosis. J Pathology 2000; 192: 90-96
  17. Braidman IP, Baris C, Wood L, et al. Preliminary evidence for impaired oestrogen receptor-a expression in osteoblasts and osteocytes from men with idiopathic osteoporosis. Bone 2000; 26: 423-427
  18. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation. J Clin Endocrinol Metab 1995; 80: 3689-3698
  19. Kurla